Objective:
Evaluate whether nanopore whole-genome sequencing with adaptive sampling (AS-WGS) can detect clinically relevant genomic alterations and support tumor classification in pediatric cancers.
Approach:
- Study samples: Researchers analyzed 36 samples from 35 pediatric patients, including 31 tumor samples from patients with leukemia and solid cancers.
- Sequencing and analysis: Nanopore whole-genome sequencing with adaptive sampling (AS-WGS) targeted approximately 380 clinically relevant genomic regions while retaining genome-wide information. The team developed the open-source nf-core-oncoseq pipeline to analyze data during sequencing.
- Comparison: The researchers compared AS-WGS results with conventional diagnostic testing and used DNA methylation information for tumor classification.
Key Findings:
- Compared with conventional diagnostic testing, AS-WGS detected all 20 previously identified gene fusions, mutations in 58 of 59 affected genes, and 20 of 21 large copy-number alterations.
- The assay detected mutations present in as little as 5% of sequenced DNA.
- Within 24 hours, all 20 gene fusions and all 47 evaluated mutations with variant allele frequencies above 25% had at least five supporting reads. Large chromosomal alterations could be identified within the first hour.
- Methylation-based analysis correctly classified 9 of 11 acute lymphoblastic leukemia samples and 8 of 12 solid tumors.
- Researchers estimated sequencing costs at approximately CAD $1,700 per sample, compared with more than CAD $5,000 for combined conventional approaches.
Interpretation:
The study authors reported that AS-WGS provided early findings on clinically relevant alterations and combined detection of major genomic alteration classes with methylation-based tumor classification in one workflow.
Limitations:
- Some variants required manual review, and low-frequency mutation detection could require 72 hours of sequencing.
- DNA quality and sequencing performance affected results.
- Further clinical validation is needed to determine whether AS-WGS can replace existing diagnostic workflows and improve treatment decisions.
Conclusion:
In this pediatric cancer sample set, AS-WGS detected many clinically relevant genomic alterations, with some findings available within hours, and supported methylation-based tumor classification.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
